atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from Phase 1 Single and Multiple Ascending Dose Trial of GRX-917
Posted:
Atai Life Sciences a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, and its subsidiary GABA Therapeutics, announced final positive results from a Phase 1 clinical trial of GRX-917 that were previously announced as preliminary results during atai’s R&D day. Read more here.
Capital planning in healthcare is not merely an administrative obligation—it is a strategic discipline that shapes clinical capabilities, operational resilience and financial health.
Recognising and addressing common planning mistakes is essential to sustaining high-quality, efficient care in an increasingly complex…
The US Food and Drug Administration has approved the first eye drop that could allow users to ditch their bifocals—or at least rely on them far less often. Developed by the pharmaceutical company LENZ, VIZZ is an aceclidine ophthalmic treatment in the form of…
Attendees
Sponsors and Exhibitors
Contact us